Shubladze A K, Zaĭtseva N S, Maevskaia T M, Cheglakov Iu A, Murav'eva T V
Vopr Virusol. 1978 Jan-Feb(1):63-8.
The mechanism of specific vaccine therapy in herpetic eye disease was studied. The effectiveness of the therapy in the observation period of 3 to 8 years was established. In 71 (62%) of 114 patients relapses of the disease disappeared completely, in 32 (26%) became less frequent and in 11 (10%) their frequency did not change. The clinical course of relapses in all cases became milder. The vaccination courses given were shown not to influence the level of virusneutralizing antibody but to induce the appearance in the lacrimal fluid of immunoglobulins G and M and to increase considerably the level of IgA. The vaccint therapy enhanced the reactions of cell-mediated immunity which was manifested in increased specific blasttransformation of lymphocytes (up to 18%) and reduced the migrational capacity of leucocytes to inactivated antigen of herpesvirus. The effect of the vaccine persisted only for a few months. The immunological and clinical analyses showed that it was expedient to give vaccine in courses at 6--12-month intervals after an attack of herpes.
对疱疹性眼病特异性疫苗治疗的机制进行了研究。确定了该疗法在3至8年观察期内的有效性。114例患者中，71例（62%）疾病复发完全消失，32例（26%）复发频率降低，11例（10%）复发频率未改变。所有病例复发的临床过程均变轻。所给予的疫苗接种疗程未显示会影响病毒中和抗体水平，但可诱导泪液中免疫球蛋白G和M的出现，并显著提高IgA水平。疫苗治疗增强了细胞介导免疫反应，表现为淋巴细胞特异性母细胞转化增加（高达18%），并降低了白细胞对疱疹病毒灭活抗原的迁移能力。疫苗的效果仅持续几个月。免疫和临床分析表明，疱疹发作后每隔6至12个月进行疗程性疫苗接种是适宜的。
